New drug for smoking cessation: rimonabant

P. Tonnesen (Gentofte, Denmark)

Source: Annual Congress 2005 - New strategies and drugs for smoking cessation
Session: New strategies and drugs for smoking cessation
Session type: Hot topics
Number: 1314
Disease area: Airway diseases

Slide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Tonnesen (Gentofte, Denmark). New drug for smoking cessation: rimonabant. Annual Congress 2005 - New strategies and drugs for smoking cessation

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
New drug for smoking cessation: varenicline
Source: Annual Congress 2005 - New strategies and drugs for smoking cessation
Year: 2005

Pharmacological treatment for smoking cessation
Source: Eur Respir Mon; 2008: 42: 74–97
Year: 2008

Pharmacological treatments for tobacco dependence
Source: Eur Respir Rev 2008; 17: 192-198
Year: 2008



Exercise in addition to nicotine replacement therapy improves success rates in smoking cessation
Source: Annual Congress 2006 - How to treat tobacco smokers
Year: 2006


Relapse rates following different types of medication treatment through a smoking cessation program
Source: Annual Congress 2006 - How to treat tobacco smokers
Year: 2006


Smoking cessation according to nicotine dependence: experience of a smoking cessation program
Source: Virtual Congress 2020 – From tobacco control policy to smoking cessation
Year: 2020


Cytisine is an effective smoking cessation medication: more evidence now than ever before
Source: International Congress 2017 – Smoking cessation treatment and e-cigarettes
Year: 2017

A pharmacological with nicotine or bupropion versus an integrated pharmacological and psychological program for smoking cessation
Source: Eur Respir J 2002; 20: Suppl. 38, 579s
Year: 2002

Harm reduction in difficult-to-stop smokers
Source: Annual Congress 2005 - MP16 - Harm reduction in difficult-to-stop smokers
Year: 2005

Varenicline x combination of nicotine patch and bupropione: results of a smoking cessation private program
Source: Annual Congress 2009 - Smoking cessation
Year: 2009


Causes of quitting treatment with varenicline in a smoking cessation clinic
Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation
Year: 2009

Improvement of quit smoking rate by combining varenicline and nicotine replacement therapy
Source: Annual Congress 2009 - Smoking cessation
Year: 2009


Electronic cigarettes for smoking cessation: an opportunity to readdress smoking cessation treatment
Source: Eur Respir J, 56 (4) 2000098; 10.1183/13993003.00098-2020
Year: 2020



Nonpharmacological smoking cessation interventions in clinical practice
Source: Eur Respir Rev 2008; 17: 187-191
Year: 2008



Clinical and pathological determinants of abstinence rate in smoking cessation with varenicline
Source: Annual Congress 2010 - Smoking cessation interventions
Year: 2010

Review of current smoking cessation guidelines
Source: Eur Respir Mon; 2008: 42: 35–43
Year: 2008

In respiratory patients short term complete abstinence from smoking does not depend on the stage of change
Source: Annual Congress 2005 - Smoking cessation in respiratory diseases: methods and results
Year: 2005


Zyban and smoking cessation: predictors of success
Source: Eur Respir J 2003; 22: Suppl. 45, 126s
Year: 2003